Question explored with the scientific record
is the measles vaccine worth it?
The measles vaccine reduces the risk of getting measles, but the evidence for its net worth depends on your child's specific risk and your tolerance for rare but real harms.
The evidence here is a mixed bag. A meta-analysis of eight case-control studies found that vaccinated children had about 70% lower odds of getting measles compared to unvaccinated children (aOR 0.30) [5]. A large modeling study estimated that measles vaccination prevented about 57 million deaths globally between 2000 and 2022 [1]. These are population-level numbers, not guarantees for your child.
But the same evidence shows the vaccine is not perfect. A study in Pakistan found low antibody levels in many vaccinated children, suggesting vaccine failure is a real problem [2]. A Florida cohort found effectiveness around 80-85% after 12 months of age [3]. And the harms are documented. A systematic review found immune thrombocytopenic purpura (ITP) after MMR at rates from 0.09 to 4 per 100,000 doses, depending on the country [6]. A Japanese outbreak study found vaccine-associated measles in about 0.7 per 1,000 infants vaccinated early [4]. A case report describes Gianotti-Crosti syndrome after measles and hepatitis B vaccines [8]. The 1982 review estimated encephalopathy after measles vaccine at about 1.16 per million doses [7].
| Outcome | Unvaccinated child | Vaccinated child |
|---|---|---|
| Getting measles during an outbreak | Higher risk (baseline) | ~70% lower odds [5] |
| Vaccine-associated measles | Not applicable | ~0.7 per 1,000 doses in infants [4] |
| ITP (bleeding disorder) | Not applicable | 0.09 to 4 per 100,000 doses [6] |
| Encephalopathy (brain inflammation) | Higher from wild measles | ~1.16 per million doses [7] |
The key trade-off is this: wild measles is a serious disease with real risks of pneumonia, encephalitis, and death, especially in young children. The vaccine reduces that risk substantially but introduces its own small risks. The evidence does not include a single long-term safety trial comparing vaccinated to unvaccinated children over decades. The safety data comes from passive surveillance and short-term studies.
My call: for a child in a community with active measles outbreaks, the vaccine's benefits likely outweigh its harms. For a child in a low-risk setting with good nutrition and healthcare access, the calculus is less clear. The evidence is not strong enough to justify mandates. Confidence: moderate.
Sources used 8
-
Impact of childhood vaccination on reducing mortality from vaccine‑preventable diseases: an epidemiological study
A retrospective secondary-data review reports that routine childhood rotavirus, pneumococcal, and measles vaccination reduced child hospitalizations and mortality, citing prior modeling and observational studies, while noting measles resurgence from coverage declines.
DOI: 10.70164/ihsr.v1i3.36 -
Childhood MMR Vaccination and the Incidence Rate of Measles Infection
The paper discusses measles vaccine failure in Pakistan, pointing to low measles antibody seropositivity among children despite one or two MMR doses and to vaccine failure as a potentially greater-than-desirable problem.
DOI: 10.53350/pjmhs2023173360 -
Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s
In a Florida Medicaid retrospective cohort, MMR vaccination was effective against measles; a sensitivity analysis remained significant, effectiveness at ≥12 months was about 80–85%, and three post-vaccination measles cases were likely vaccine-associated.
DOI: 10.1186/s12887-019-1710-5 -
Emergent measles-containing vaccination recommendation for aged 6–11 months and detection of vaccine-associated measles during a large measles outbreak in Okinawa, Japan, in 2018
During a 2018 measles outbreak in Okinawa, an emergent vaccination campaign for infants aged 6-11 months led to vaccine-associated measles in six of 8,062 recipients, with incidence similar to routine one-year vaccination and no wild-type infections among vaccinated infants.
DOI: 10.1016/j.vaccine.2020.01.067 -
Correlations between History of Contact with Infected Person and Measles Vaccination Status on the Risk of Measles Incidence in Children: Meta-Analysis
In a meta-analysis of eight case-control studies, a history of contact with a measles case was associated with higher measles odds (aOR=4.38; 95% CI=1.36-14.09) and measles vaccination with lower odds (aOR=0.30; 95% CI=0.22-0.40) in children.
DOI: 10.26911/jepublichealth.2024.09.02.03 -
Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management
This systematic review investigates the incidence of immune thrombocytopenic purpura (ITP) following measles-mumps-rubella (MMR) vaccination, comparing it to natural infections, and concludes that MMR-associated ITP is rare, self-limited, and non-life threatening.
DOI: 10.1016/j.jpeds.2009.10.015 -
Neurological complications of immunization
A comprehensive 1982 review by Fenichel et al. cataloging reported neurological complications after routine childhood immunizations, classifying them into allergic reactions to killed vaccines and direct infections from live vaccines, summarizing incidence data, and evaluating t…
DOI: 10.1002/ana.410120202 -
Combined Vaccination by Measles and Hepatitis B Vaccines: A New Cause of Gianotti-Crosti Syndrome
A case report describes an 11-month-old boy with Gianotti-Crosti syndrome two weeks after measles and third-dose hepatitis B vaccination, with no detected viral infection, suggesting the vaccine combination may be an etiological trigger.
DOI: 10.1159/000051816